Herpes zoster causes major morbidity among older people (BOX 1). Identification of more-effective strategies to prevent zoster among this population is, therefore, essential. In a GlaxoSmithKline-funded study, published recently in the New England Journal of Medicine, Anthony Cunningham and colleagues reported impressive efficacy of an adjuvanted herpes zoster subunit vaccine in adults aged 70 years and older 1 . In the study, known as ZOE-70, 13,900 participants with a mean age of 75.6 years were recruited from 18 countries and randomly allocated to receive either two doses of an investigational herpes zoster subunit vaccine (HZ/su; GSK vaccines) or placebo 1 . In contrast to the currently used herpes zoster vaccine, which contains live attenuated virus of the Oka VZV strain, the new vaccine contains 50 µg of recombinant VZV glyco protein E subunit in the liposome-based AS01b adjuvant system, which is designed to enhance CD4 + T-cell and humoral immune responses to recombinant proteins. Over 3.7 years of follow-up, only 23 confirmed cases of herpes zoster were observed in the vaccinated group, whereas 223 cases were confirmed in the placebo group, meaning that the vaccine efficacy (VE) for preventing herpes zoster in individuals who had received both vaccine doses was 89.8% (95% CI 84.2-93.7%).
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To increase statistical power of the study, the authors conducted several prespecified pooled analyses of participants from ZOE-70 and the ZOE-50 trial, which was conducted averaging pain severity and duration scores based on the Zoster Brief Pain Inventory), tends to overestimate VE 3 . Although other studies have considered the effect of zoster vaccine on activities of daily living or health-related quality of life, the main effect of zoster vaccine on these endpoints is through preventing zoster, rather than by attenuating severity or duration of illness 3 , which supports the approach Cunningham and co-investigators took.
The results of ZOE-70 trial are noteworthy for several reasons: first, they demonstrate a marked increase in efficacy over the current live attenuated Oka/Merck VZV vaccine, which is licensed for adults aged 50 years and older. In the landmark Shingles Prevention Study, the Oka/Merck VZV vaccine reduced herpes zoster incidence by 51.1%, burden of illness attributed to shingles by 61.1%, and post-herpetic neuralgia by 66.5% 4 . Second, efficacy of the new subunit vaccine did not diminish with increasing age: VE was 90.0% in those aged 70-79 years and 89.1% in participants aged 80 years or older. By contrast, the age-stratified VE estimates for the current live attenuated vaccine for reducing herpes zoster incidence are 69.8% in participants aged 50-59 years 5 , 63.9% among subjects aged 60-69 years and 37.6% among those aged 70 years and over 4 . Establishing an adequate immune response to vaccines in older people is challenging: in general, the size of the response (defined by antibody titre or the level of cell-mediated immunity induced by the vaccine), its duration and its quality are lower in older people than in younger people, regardless of vaccine type 6 . The high efficacy of the new HZ/su vaccine suggests that the vaccine is able to overcome some of the processes associated with by the same group of investigators, and used methods identical to ZOE-70 to investigate efficacy of the HZ/su vaccine in adults aged ≥50 years 2 . The results of the ZOE-50 trial were published last year and showed a marked reduction in herpes zoster among vaccinated participants in this age group (VE 97.2%; 95% CI 93.7-99.0). Combined analysis of all 16,596 ZOE-50 and ZOE-70 trial participants aged ≥70 years showed a VE against herpes zoster of 91.3% (95% CI 86.8-94.5%). In another prespecified pooled analysis of ZOE-50 and ZOE-70 trial participants aged ≥50 years, VE against post-herpetic neuralgia was 88.8% (95% CI 68.7-97.1%).
The choice of primary end point in the present study -reduction in herpes zoster incidence -is supported by a recent review of endpoints in zoster vaccine studies 3 , which concluded that use of the main alternative endpoint, burden of illness (determined by • The incidence of the disease rises dramatically with age -the lifetime zoster risk for those aged ≥85 years is approaching 50% 8 • The risk of post-herpetic neuralgia -a debilitating neuropathic pain syndrome -increases markedly after the age of 50 years 9 • Case fatality of herpes zoster is also highly age-correlated: more than 95% of deaths occur in people aged ≥60 years 10 • T-cell mediated immunity, which controls reactivation of the varicella zoster virus (VZV) from latency and promotes recovery after herpes zoster, declines progressively with age 6 • Cell-mediated immune response to the currently licensed live attenuated zoster vaccine is lower in older age groups, and the effects of the vaccine wane over time 6 senescence of adaptive immunity, notably the high background inflammatory state implicated in age-related alterations to T-cell immunity 7 , which can inhibit vaccination-associated T-cell activation in older people. Better understanding of the biology that underlies the findings from ZOE-70 could, therefore, have more general implications for improving vaccine efficacy in the elderly.
Besides older people, the HZ/su vaccine could benefit other groups with impaired cell-mediated immunity-such as individuals on immunosuppressive therapies or with various haematological malignancies -who may be at high risk of herpes zoster but in whom live vaccine is contraindicated. The HZ/su vaccine is not a live vaccine, so the virus cannot replicate. The vaccine can, therefore, theo retically be used in immunocompromised people, although this was not tested in the trial, and safety and efficacy in this group would require further investigation.
One potential disadvantage of the HZ/su vaccine is the higher frequency of solicited injection-site and systemic reactions, most frequently fatigue, reported within 7 days of the vaccine compared with placebo (79.0% versus 29.5%). These adverse reactions had a tendency to be transient, mild to moderate reactions, with a median duration of 2-3 days for injection site reactions and 1-2 days for systemic reactions. Systemic reactions were more often reported in HZ/su vaccine recipients (53.0%) 1 than in recipients of the live attenuated vaccine (25%) 4 . Importantly, rates of serious adverse events, immune-mediated disease and deaths did not differ between HZ/su vaccine and placebo groups.
Another potential issue with the Hz/su vaccine is compliance: the subunit vaccine requires two doses given 2 months apart, rather than a single dose as is the case for live attenuated vaccine. Encouragingly, VE results for the total vaccinated cohort (including the ~5% of participants who received only one vaccine) remained high at 87.7% (95% CI 82.0-92.0%).
The duration of protection provided by the HZ/su vaccine remains an open question. Efficacy of the live attenuated vaccine declines markedly between 3 and 11 years after vaccination. Although any reduction of HZ/su vaccine-induced immunity would start from a higher baseline, accurate assessment of the likely duration of protection is key to inform cost-effectiveness estimates and, ultimately, the design of effective public health programmes. The HZ/su vaccine offers the exciting prospect of notably reducing the population burden of zoster complications, especially in settings that already achieve a relatively high vaccine uptake.
Identification of moreeffective strategies to prevent zoster among older adults is … essential
